{"entity":{"id":"ror1","kind":"target","name":"ROR1","aka":[],"tldr":"ROR1 is a fetal pseudo-kinase receptor re-expressed on over 90% of chronic lymphocytic leukaemias, 30 to 50% of diffuse large B-cell lymphomas and 40 to 60% of triple-negative breast cancers, and largely absent from healthy adult tissue. Zilovertamab vedotin uses it as an ADC address, in phase 3 in large B-cell lymphoma; whether expression level predicts benefit is unproven.","summary":"ROR1 is an oncofetal receptor tyrosine kinase-like protein, a Wnt5a pseudo-kinase receptor that drives survival signalling in CLL and mantle cell lymphoma and is largely absent from normal adult tissue. Surface expression is seen in over 90% of CLL, 30-50% of DLBCL, and 40-60% of TNBC by IHC, with NSCLC expression also reported. Zilovertamab vedotin (MK-2140), an ADC, is in phase 3 in DLBCL, and the TNBC and NSCLC expression supports solid-tumour programmes. Because the receptor is a pseudo-kinase, it is used as a delivery address rather than a signalling target, and whether expression level predicts ADC benefit remains to be shown. The simple version is an embryonic receptor that many cancers re-express, giving ADCs a target largely missing from healthy cells.","asOf":"2026-09-04","wikipedia":"https://en.wikipedia.org/wiki/ROR1","links":[{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/ROR1"}],"tags":["adc-target"],"related":[],"cancers":["dlbcl","cll","tnbc"],"sections":[],"technologies":[],"targets":[],"drugs":["zilovertamab-vedotin"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct07510802"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"symbol":"ROR1","role":[],"sources":[],"specificity":"tumour-associated","distribution":"few-types","specificityNote":"Tumour-associated overexpression: 1 cell-killing or cell-finding medicine (Zilovertamab vedotin) aim at the antigen, which HPA finds with no normal tissue stained high; the medicine relies on the tumour carrying more of it than the normal tissue it shares it with. HPA ROR1: RNA tissue enhanced (parathyroid gland 23 nTPM); no normal tissue stained high. Distribution: 3 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Leukaemia, Lymphoma, Breast cancer (all types)); Open Targets associates it with 0 specific cancer types at or above 0.5. (Rule 5 of scripts/fetch-target-specificity.ts.)","specificitySources":[{"label":"Human Protein Atlas ROR1 tissue","url":"https://www.proteinatlas.org/ENSG00000185483-ROR1/tissue","note":"RNA tissue and blood lineage specificity, normal tissue antibody staining (version 25.1, CC BY-SA 3.0)"},{"label":"Human Protein Atlas ROR1 pathology","url":"https://www.proteinatlas.org/ENSG00000185483-ROR1/pathology","note":"patients per staining level per cancer type (version 25.1, CC BY-SA 3.0)"},{"label":"Open Targets ENSG00000185483 associations","url":"https://platform.opentargets.org/target/ENSG00000185483/associations","note":"cancer associations at or above 0.5 (CC0)"}],"hgnc":"HGNC:10256","ensembl":"ENSG00000185483","uniprot":"Q01973","entrez":"4919","firstDescribed":1992,"firstDescribedBasis":"sequence","firstDescribedNote":"Earliest sequence paper UniProt cites for the protein: Masiakowski et al, J. Biol. Chem, 1992, \"A novel family of cell surface receptors with tyrosine kinase-like domain\".","firstDescribedSource":"https://pubmed.ncbi.nlm.nih.gov/1334494/","biology":"Wnt5a pseudo-kinase receptor; drives survival signalling in CLL and MCL.","whereFound":["CLL","Mantle cell lymphoma","DLBCL","TNBC","NSCLC"],"targetClass":"surface-antigen","prevalence":[{"cancerId":"cll","pct":">90","measure":"Surface expression","source":"https://en.wikipedia.org/wiki/ROR1"},{"cancerId":"dlbcl","pct":"30-50","measure":"IHC, any expression","source":"https://en.wikipedia.org/wiki/ROR1"},{"cancerId":"tnbc","pct":"40-60","measure":"IHC, any expression","source":"https://en.wikipedia.org/wiki/ROR1"}]},"route":"/targets/ror1/","neighbours":{"cancer":[{"id":"cll","kind":"cancer","name":"Chronic lymphocytic leukaemia","route":"/cancers/cll/"},{"id":"dlbcl","kind":"cancer","name":"Diffuse large B-cell lymphoma","route":"/cancers/dlbcl/"},{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/"}],"drug":[{"id":"zilovertamab-vedotin","kind":"drug","name":"Zilovertamab vedotin","route":"/drugs/zilovertamab-vedotin/"}],"trial":[{"id":"nct07510802","kind":"trial","name":"Dual-Target CAR-NK Cells for Advanced Breast Cancer HER2+ TNBC","route":"/trials/nct07510802/"},{"id":"waveline-003","kind":"trial","name":"waveLINE-003","route":"/trials/waveline-003/"}],"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"}],"person":[{"id":"stanley-riddell","kind":"person","name":"Stanley R. Riddell","route":"/people/stanley-riddell/"}],"institution":[{"id":"ucsd-moores","kind":"institution","name":"UC San Diego Moores Cancer Center","route":"/institutions/ucsd-moores/"}]}}